Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP13 | P45452 | 5/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3379808 | 0.88 | ALDH1A1 (0.52) | MEN1KMT2ALMNATEAD1SMN1; SMN2 | |
| SCHEMBL18487083 | 0.78 | SMN1; SMN2 (0.61) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL7826084 | 0.77 | ALDH1A1 (0.64) | MEN1KMT2ALMNASMN1; SMN2ACHE | |
| SCHEMBL2397595 | 0.74 | GAA (0.56) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL6297127 | 0.74 | ESR1 (0.59) | MEN1KMT2ALMNATEAD1SMN1; SMN2 | |
| SCHEMBL7453335 | 0.72 | MMP9 (0.68) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1967123 | 0.72 | LMNA (0.68) | MEN1KMT2ALMNAALDH1A1GAA | |
| SCHEMBL834256 | 0.71 | POLB (0.59) | MEN1KMT2ALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL3257686 | 0.71 | ACHE (0.73) | MEN1KMT2ALMNAACHEALDH1A1 | |
| SCHEMBL740682 | 0.69 | KMT2A (0.51) | MEN1KMT2ALMNAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | MEN1 608/4885KMT2A 386/4885LMNA 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.